Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Accumulated Expenses (2016 - 2025)

Organogenesis Holdings (ORGO) has 10 years of Accumulated Expenses data on record, last reported at $49.5 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 25.55% year-over-year to $49.5 million; the TTM value through Dec 2025 reached $49.5 million, up 25.55%, while the annual FY2025 figure was $49.5 million, 25.55% up from the prior year.
  • Accumulated Expenses reached $49.5 million in Q4 2025 per ORGO's latest filing, up from $40.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $49.5 million in Q4 2025 and bottomed at $2.4 million in Q1 2024.
  • Average Accumulated Expenses over 5 years is $32.1 million, with a median of $34.1 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: tumbled 91.44% in 2024, then skyrocketed 1171.85% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $37.3 million in 2021, then fell by 29.08% to $26.4 million in 2022, then increased by 13.71% to $30.1 million in 2023, then soared by 31.19% to $39.5 million in 2024, then increased by 25.55% to $49.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $49.5 million in Q4 2025, $40.3 million in Q3 2025, and $26.3 million in Q2 2025.